A股異動 | 多名股東擬減持,明月鏡片大跌超11%,跌幅居市場首位
“中國鏡片第一股”明月鏡片(301101.SZ)目前大跌11.6%,跌幅居市場首位,總市值跌破百億元關口。消息面上,明月鏡片昨日晚間披露公吿稱,公司控股股東上海實業、實際控制人謝公晚、謝公興、曾少華及其一致行動人丹陽志明,公司董事、副總經理、董事會祕書曾哲,公司股東諾偉其擬合計減持不超4.8821%公司股份。需要注意的是,公吿中披露擬減持股份數量不代表最終實際減持股份數。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.